Regular cholesterol testing is essential for diagnosing and monitoring conditions such as high cholesterol, which is a major risk factor for cardiovascular diseases. It helps healthcare professionals assess an individual's cholesterol levels and determine the appropriate treatment plan. Cholesterol testing is also important for monitoring the effectiveness of lifestyle changes and medication interventions. The market's significance lies in its contribution to the early detection and management of cholesterol-related health conditions, promoting better health outcomes and reducing the risk of cardiovascular diseases.
Access Full Report: https://www.databridgemarketresearch.com/reports/global-cholesterol-testing-market
Data Bridge Market Research analyses that the Global Cholesterol Testing Market value was USD 7,461.10 million in 2021 and will be anticipated to reach USD 14,193.03 million in 2029 with a CAGR of around 8.37% during the forecast period of 2022 to 2029. The rising incidence of cardiovascular diseases, including high cholesterol levels, is driving the demand for cholesterol testing. As awareness about the risks of cardiovascular diseases grows, individuals are seeking early detection and management of high cholesterol levels.
Key Findings of the Study
Technological advancements in cholesterol testing are expected to drive the market's growth rate
Technological advancements in cholesterol testing have revolutionized the way cholesterol levels are measured and monitored. The development of point-of-care testing devices and home test kits has made cholesterol testing more convenient, allowing individuals to check their cholesterol levels at their convenience. These innovations have increased accessibility and adoption of cholesterol testing, as individuals can now easily monitor their cholesterol levels, leading to a higher demand for cholesterol testing products and services.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Test Kits, Testing Strips), Test (Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL), Test Type (Non-Invasive, Invasive), Prescription Mode (Over The Counter, Prescription Based), End-Users (Clinics, Hospitals, Ambulatory Centers, Homecare, Diagnostic Centers)
|
|
Countries Covered
|
The countries covered in the cholesterol testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Boston Scientific Corporation (U.S.), Medtronic (U.S.) Koninklijke Philips N.V. (Netherlands) F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), AstraZeneca (U.K.), LivaNova PLC (U.K.), BIOTRONIK SE & Co. KG (Germany) ACON Laboratories, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Spectra Laboratories, Inc. (U.S.) Eurofins Scientific (Luxembourg), Randox Laboratories Ltd (U.K.), Bio-Reference Laboratories (U.S.), Clinical Reference Laboratory (U.S.), Abbott India Limited (India), Danaher (U.S.) Prima Lab SA (Switzerland), Sigma Aldrich (U.S.), PTS Diagnostics (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The cholesterol testing market is segmented on the basis of product type, test, test type, prescription mode, and end-users.
- On the basis of product type, the cholesterol testing market is segmented into test kits, and testing strips. The test kits is expected to dominate the cholesterol testing market with 58.7% market share due to test kits offer a more comprehensive approach to cholesterol testing, including measurement of multiple cholesterol parameters such as total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in the forecast period of 2022 to 2029.
- On the basis of test, the cholesterol testing market is segmented into total cholesterol test, high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL). The cholesterol test segment dominates due to its essential role in assessing overall cholesterol levels. Total cholesterol testing provides a comprehensive measurement of both HDL and LDL cholesterol, which are crucial indicators of cardiovascular health.
- On the basis of test type, the cholesterol testing market is segmented into non-invasive, and invasive. The non-invasive segment dominates the cholesterol testing market due to their ease of use, accurate results, and reduced risk of complications, leading to the dominance of the non-invasive segment in the market in the forecast period of 2022 to 2029.
- On the basis of prescription mode, the cholesterol testing market is segmented into over the counter, and prescription based. Prescription-based segment dominates the cholesterol testing market because cholesterol testing is considered a medical diagnostic procedure that requires interpretation and guidance from healthcare professionals from 2022 to 2029.
In 2022 the prescription-base segment dominates the prescription mode segment in the cholesterol testing market
In 2022 the prescription-base segment dominates the prescription mode segment in the cholesterol testing market due to cholesterol testing is considered a medical diagnostic procedure that requires interpretation and guidance from healthcare professionals. Prescription-based testing ensures appropriate screening, diagnosis, and management of cholesterol levels, leading to the dominance of this segment in the market, where medical expertise is crucial for accurate interpretation and treatment planning in the forecast period of 2022 to 2029.
- On the basis of end-users, the cholesterol testing market is segmented into clinics, hospitals, ambulatory centers, homecare, and diagnostic centers. The diagnostic centers segment dominates the cholesterol testing market due to the diagnostic centers specialize in conducting various diagnostic tests, including cholesterol testing, offering specialized equipment, expertise, and a dedicated focus on diagnostic services from 2022 to 2029.
In 2022 diagnostic centers segment dominates the cholesterol testing market in the cholesterol testing market
In 2022 diagnostic centers segment dominates the cholesterol testing market in the cholesterol testing market due to diagnostic centers segment dominates the cholesterol testing market due to the diagnostic centers specialize in conducting various diagnostic tests, including cholesterol testing, offering specialized equipment, expertise, and a dedicated focus on diagnostic services. Diagnostic centers provide convenient access to cholesterol testing for patients, healthcare professionals, and researchers, leading to their dominance in the market as a preferred end-user segment in 2022 to 2029.
Major Players
Data Bridge Market Research recognizes the following companies as the major global cholesterol testing market players in global cholesterol testing market are Boston Scientific Corporation (U.S.), Medtronic (U.S.) Koninklijke Philips N.V. (Netherlands) F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), AstraZeneca (U.K.), LivaNova PLC (U.K.), BIOTRONIK SE & Co. KG (Germany) ACON Laboratories, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.),
Market Development
- In May 2022, Goodbody Health introduced its core UK Health "MOT" test, which includes innovative diabetes and cholesterol tests conducted in clinics. The test delivers results within minutes and helps assess an individual's risk of developing cardiac health problems or diabetes in the next decade.
- In March 2022, Rosalind Franklin University's Community Care Connection and a partnership with NorthShore University Health System continued to provide essential medical care to underserved communities in North Chicago. The Care Coach, a mobile health unit staffed by licensed healthcare professionals, received $680,000 in financing from NorthShore's Community Investment Fund.
Regional Analysis
Geographically, the countries covered in the global cholesterol testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America dominates the cholesterol testing market during the forecast period 0f 2022 to 2029
North America maintains its dominance in the cholesterol testing market, primarily driven by the growing geriatric population in the region. As the elderly population increases, the number of individuals with cholesterol-related conditions also rises. This demographic shift leads to a higher demand for cholesterol testing services and products, contributing to the region's continued market growth and dominance in terms of market share and revenue.
Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period of 2022 to 2029
Asia-Pacific is expected to experience significant growth in the cholesterol testing market, driven by government initiatives to raise awareness about cholesterol-related issues. Countries like China and Japan, which have a large aging population, are actively developing cost-effective cholesterol testing devices. This combination of increasing awareness and the availability of affordable testing solutions is likely to fuel the market's growth in the Asia-Pacific region during the forecast period.
For more detailed information about the global cholesterol testing market report, click here – https://www.databridgemarketresearch.com/reports/global-cholesterol-testing-market
